Jump to Main Content
CdTe quantum dots as fluorescent probes to study transferrin receptors in glioblastoma cells General subjects
- Cabral Filho, Paulo E., Cardoso, Ana L.C., Pereira, Maria I.A., Ramos, Ana P.M., Hallwass, Fernando, Castro, M. Margarida C.A., Geraldes, Carlos F.G.C., Santos, Beate S., Pedroso de Lima, Maria C., Pereira, Giovannia A.L., Fontes, Adriana
- Biochimica et biophysica acta 2016 v.1860 no.1 pp. 28-35
- flow cytometry, fluorescence, fluorescent dyes, humans, molecular biology, neoplasm cells, neoplasms, quantum dots, receptors, transferrin
- Overexpression of transferrin receptors (TfRs), which are responsible for the intracellular uptake of ferric transferrin (Tf), has been described in various cancers. Although molecular biology methods allow the identification of different types of receptors in cancer cells, they do not provide features about TfRs internalization, quantification and distribution on cell surface. This information can, however, be accessed by fluorescence techniques. In this work, the quantum dots (QDs)' unique properties were explored to strengthen our understanding of TfRs in cancer cells.QDs were conjugated to Tf by covalent coupling and QDs-(Tf) bioconjugates were applied to quantify and evaluate the distribution of TfRs in two human glioblastoma cells lines, U87 and DBTRG-05MG, and also in HeLa cells by using flow cytometry and confocal microscopy.HeLa and DBTRG-05MG cells showed practically the same TfR labeling profile by QDs-(Tf), while U87 cells were less labeled by bioconjugates. Furthermore, inhibition studies demonstrated that QDs-(Tf) were able to label cells with high specificity.HeLa and DBTRG-05MG cells presented a similar and a higher amount of TfR than U87 cells. Moreover, DBTRG-05MG cells are more efficient in recycling the TfR than the other two cells types.This is the first study about TfRs in human glioblastoma cells using QDs. This new fluorescent tool can contribute to our understanding of the cancer cell biology and can help in the development of new therapies targeting these receptors.